Santhera Pharmaceuticals Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dario Eklund
- Full Time Employees
- 78
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Hohenrainstrasse 24 Pratteln Switzerland 4133
- IPO Date
- Apr 17, 2014
- Website
- santhera.com
- Similar Companies
- Business
- Santhera Pharmaceuticals Holding AG is a biopharmaceutical company primarily engaged in the development, manufacturing, and commercialization of specialty pharmaceutical products for rare neuromuscular and pulmonary diseases. The company's main products and services include the development and marketing of innovative therapies such as Raxone (idebenone) for the treatment of Duchenne muscular dystrophy and Leber's hereditary optic neuropathy; Puldysa (famotidine) for limb-girdle muscular dystrophy; and various pipeline candidates targeting rare mitochondrial and neuromuscular disorders. Santhera operates in global pharmaceutical markets, with a focus on Europe, North America, and other international regions. Founded in 1996, the company is headquartered in Pratteln, Switzerland. In recent developments, over the last 1-2 years, Santhera has strategically repositioned its product portfolio by advancing late-stage clinical programs and exploring new partnerships to enhance its market presence. The company has been focusing on expanding its rare disease pipeline, including recent updates on clinical trials and potential regulatory filings. Santhera has also been involved in strategic alliances for co-commercialization and distribution in key markets to strengthen its commercial operations. There have been no recent name changes or major reorganizations reported, but the company continues to prioritize innovation and geographic expansion in specialty pharmaceuticals. Santhera operates within the pharmaceutical and biotechnology industry, serving patients with rare and debilitating diseases, alongside healthcare providers and payers. Its business segments include specialty pharmaceuticals for rare neuromuscular and pulmonary conditions, with a growing pipeline emphasizing orphan drug development. The company is publicly traded under the ticker SPHDF. Its operational scope extends across multiple countries, leveraging partnerships to maximize market access, regulatory compliance, and patient reach worldwide. Santhera Pharmaceuticals Holding AG maintains a focus on innovation, patient-centric therapies, and strategic growth within its niche therapeutic areas.
Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
eBay heads into Q1 earnings with momentum, but macro clouds loom
Santhera reconfirms cash flow breakeven target as AGAMREE revenues near-double
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
Santhera wins backing to extend DMD drug AGAMREE to toddlers as young as two
Santhera Pharmaceuticals (OTCMKTS:SPHDF) Trading Up 35.4% – What’s Next?
Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress
BlackRock shares jump on Q4 earnings, record $14T assets under management
Santhera lands key approval for DMD treatment in Switzerland
Santhera lands key approval for DMD treatment in Switzerland
Aritzia shares rise as Q3 earnings top expectations
Santhera shares jump after $205 million Asia-Pacific licensing deal
Santhera shares jump after $205 million Asia-Pacific licensing deal
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript